{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T21:05:11Z","timestamp":1789765511751,"version":"4.0.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bulcan.2026.06.003","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T20:02:20Z","timestamp":1788206540000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cancer du canal anal m\u00e9tastatique ou en rechute inop\u00e9rable\u00a0: approches th\u00e9rapeutiques et perspectives d\u2019\u00e9volution"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4894-5841","authenticated-orcid":false,"given":"Coralie","family":"Prevost","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Vaflard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Neuzillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Delaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Bi\u00e8che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Vasseur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Vendrely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Borg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Smolenschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2026.06.003_bib0260","series-title":"Global Cancer Observatory: Cancer Today","author":"Ferlay","year":"2024"},{"key":"10.1016\/j.bulcan.2026.06.003_bib0265","series-title":"Estimations nationales de l\u2019incidence et de la mortalit\u00e9 par cancer en France m\u00e9tropolitaine entre 1990 et 2018. Volume 1\u00a0\u2013\u00a0Tumeurs solides","author":"Defossez","year":"2019"},{"key":"10.1016\/j.bulcan.2026.06.003_bib0270","unstructured":"Recommandations HAS avril 2025 relatives \u00e0 la vaccination contre les papillomavirus humains (HPV) [Internet]. [cit\u00e9 14 janv 2026. Disponible sur\u00a0: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2025-05\/vaccination_contre_les_papillomavirus_elargissement_de_la_cohorte_de_rattrapage_vaccinale_ches_les_hommes_et_femmes_jusqu_a_.pdf]."},{"issue":"6","key":"10.1016\/j.bulcan.2026.06.003_bib0275","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.cgh.2024.05.029","article-title":"Perianal fistulizing Crohn's disease\u2013associated anorectal and fistula cancers: systematic review and expert consensus","volume":"23","author":"Wong","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.bulcan.2026.06.003_bib0280","series-title":"\u00ab\u00a0Cancer du canal anal\u00a0\u00bb","author":"Moureau-Zabotto","year":"2025"},{"key":"10.1016\/j.bulcan.2026.06.003_bib0285","doi-asserted-by":"crossref","first-page":"109542","DOI":"10.1016\/j.radonc.2023.109542","article-title":"Treatment, outcome, and prognostic factors in non-metastatic anal cancer: the French nationwide cohort study FFCD-ANABASE","volume":"183","author":"Vendrely","year":"2023","journal-title":"Radiother Oncol"},{"issue":"12","key":"10.1016\/j.bulcan.2026.06.003_bib0290","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/S1470-2045(25)00605-9","article-title":"Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trial","volume":"26","author":"Kim","year":"2025","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2026.06.003_bib0295","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.dld.2025.12.019","article-title":"Induction chemotherapy followed by chemoradiotherapy in patients with locally advanced anal cancers: the PRODIGE 85-FFCD 1804-KANALRAD trial","volume":"58","author":"Medjahdi","year":"2026","journal-title":"Dig Liver Dis"},{"issue":"22","key":"10.1016\/j.bulcan.2026.06.003_bib0300","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1200\/JCO.19.03266","article-title":"International rare cancers initiative multicenter randomized phase II trial of cisplatin and fluorouracil versus carboplatin and paclitaxel in advanced anal cancer: InterAAct","volume":"38","author":"Rao","year":"2020","journal-title":"JCO"},{"key":"10.1016\/j.bulcan.2026.06.003_bib0305","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1186\/s12885-017-3566-0","article-title":"Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study)","volume":"17","author":"Kim","year":"2017","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.bulcan.2026.06.003_bib0310","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s40164-023-00413-2","article-title":"DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching study","volume":"12","author":"Kim","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.bulcan.2026.06.003_bib0315","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ejca.2021.11.019","article-title":"Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies","volume":"162","author":"Stouvenot","year":"2022","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.bulcan.2026.06.003_bib0320","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ijrobp.2018.04.076","article-title":"Extended-field chemoradiation therapy for definitive treatment of anal canal squamous cell carcinoma involving the para-aortic lymph nodes","volume":"102","author":"Holliday","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"10.1016\/j.bulcan.2026.06.003_bib0325","doi-asserted-by":"crossref","first-page":"110346","DOI":"10.1016\/j.ejso.2025.110346","article-title":"Salvage abdominoperineal resection for anal squamous cell carcinoma after radiotherapy or chemoradiotherapy: analysis of the French prospective cohort FFCD-ANABASE","volume":"51","author":"Naessens","year":"2025","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2026.06.003_bib0330","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/DCR.0000000000001010","article-title":"Salvage surgery for locoregional failure in anal squamous cell carcinoma","volume":"61","author":"Guerra","year":"2018","journal-title":"Dis Colon Rectum"},{"issue":"S3","key":"10.1016\/j.bulcan.2026.06.003_bib0335","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1245\/s10434-015-4545-9","article-title":"Interstitial brachytherapy for the treatment of locally recurrent anorectal cancer","volume":"22","author":"Bishop","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.bulcan.2026.06.003_bib0340","doi-asserted-by":"crossref","DOI":"10.1177\/15330338251349596","article-title":"Electrochemotherapy for anorectal tumors: a narrative literature review","volume":"24","author":"Ferioli","year":"2025","journal-title":"Technol Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.bulcan.2026.06.003_bib0345","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/1471-2407-10-189","article-title":"Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas","volume":"10","author":"Van Damme","year":"2010","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.bulcan.2026.06.003_bib0350","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.chest.2020.09.238","article-title":"Characteristics and long-term outcomes of pulmonary venoocclusive disease induced by mitomycin C","volume":"159","author":"Certain","year":"2021","journal-title":"Chest"},{"issue":"06","key":"10.1016\/j.bulcan.2026.06.003_bib0355","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1055\/s-2005-925474","article-title":"Drug-induced thrombotic microangiopathy","volume":"31","author":"Zakarija","year":"2005","journal-title":"Semin Thromb Hemost"},{"issue":"4","key":"10.1016\/j.bulcan.2026.06.003_bib0360","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1470-2045(17)30104-3","article-title":"Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study","volume":"18","author":"Morris","year":"2017","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.bulcan.2026.06.003_bib0365","doi-asserted-by":"crossref","first-page":"e002996","DOI":"10.1136\/jitc-2021-002996","article-title":"Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study","volume":"9","author":"Lonardi","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"13","key":"10.1016\/j.bulcan.2026.06.003_bib0370","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1158\/1078-0432.CCR-07-0374","article-title":"A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism","volume":"13","author":"Manning","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.bulcan.2026.06.003_bib0375","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(24)00081-0","article-title":"Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study","volume":"25","author":"Kim","year":"2024","journal-title":"Lancet Oncol"},{"issue":"10495","key":"10.1016\/j.bulcan.2026.06.003_bib0380","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/S0140-6736(25)00631-2","article-title":"Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303\/InterAACT-2): a global, phase 3 randomised controlled trial","volume":"405","author":"Rao","year":"2025","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.bulcan.2026.06.003_bib0385","doi-asserted-by":"crossref","first-page":"105315","DOI":"10.1016\/j.esmoop.2025.105315","article-title":"Uncovering PD-L1 among immune cell predictive biomarkers and actionable genetic alterations in anal squamous-cell carcinomas in the era of immunotherapy","volume":"10","author":"Sharma","year":"2025","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.bulcan.2026.06.003_bib0390","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41698-025-01181-4","article-title":"Comprehensive molecular landscape of anal squamous cell carcinoma: analysis of tissue and liquid biopsies from 1844 patients","volume":"9","author":"Smolenschi","year":"2025","journal-title":"NPJ Precis Onc"},{"issue":"10","key":"10.1016\/j.bulcan.2026.06.003_bib0395","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2026.06.003_bib0400","doi-asserted-by":"crossref","first-page":"100529","DOI":"10.1016\/j.esmoop.2022.100529","article-title":"A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202)","volume":"7","author":"Rao","year":"2022","journal-title":"ESMO Open"},{"issue":"7","key":"10.1016\/j.bulcan.2026.06.003_bib0405","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.3390\/cancers14071606","article-title":"Prognostic value of Fusobacterium nucleatum after abdominoperineal resection for anal squamous cell carcinoma","volume":"14","author":"Hilmi","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.bulcan.2026.06.003_bib0410","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3390\/cancers17060937","article-title":"Clinicopathologic features associated with survival for immune checkpoint blockade in patients with metastatic anal cancer","volume":"17","author":"Peddireddy","year":"2025","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.bulcan.2026.06.003_bib0415","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/s43018-025-01004-2","article-title":"Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and\/or metastatic squamous cell carcinomas: a phase 2 basket trial","volume":"6","author":"Borcoman","year":"2025","journal-title":"Nat Cancer"},{"issue":"1","key":"10.1016\/j.bulcan.2026.06.003_bib0420","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/jamaoncol.2018.4051","article-title":"Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable Human Papillomavirus 16\u2013related cancer: a phase 2 clinical trial","volume":"5","author":"Massarelli","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.bulcan.2026.06.003_bib0425","doi-asserted-by":"crossref","first-page":"S520","DOI":"10.1016\/j.annonc.2024.08.726","article-title":"660P Atezolizumab plus UCPvax telomerase CD4 TH1-inducer cancer vaccine for the treatment of chemorefractory HPV+ cancers: safety and efficacy results of the VolATIL phase II study","volume":"35","author":"Mansi","year":"2024","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2026.06.003_bib0430","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1001\/jamaoncol.2024.6998","article-title":"Novel combination immunotherapy and clinical activity in patients with HPV-associated cancers: a nonrandomized clinical trial","volume":"11","author":"Floudas","year":"2025","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2026.06.003_bib0435","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/ijc.34781","article-title":"Pathogenic alterations in PIK3CA and KMT2C are frequent and independent prognostic factors in anal squamous cell carcinoma treated with salvage abdominoperineal resection","volume":"154","author":"Hamza","year":"2024","journal-title":"Int J Cancer"},{"issue":"8","key":"10.1016\/j.bulcan.2026.06.003_bib0440","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/bjc.2015.20","article-title":"HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53","volume":"112","author":"Meulendijks","year":"2015","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.bulcan.2026.06.003_bib0445","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/j.1460-2075.1995.tb07026.x","article-title":"Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with high levels of p16INK4\/MTS1 tumour suppressor gene product","volume":"14","author":"Parry","year":"1995","journal-title":"EMBO J"},{"issue":"12","key":"10.1016\/j.bulcan.2026.06.003_bib0450","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1158\/1078-0432.CCR-24-2575","article-title":"Time dependency for human papillomavirus circulating tumor DNA detection after chemoradiation as a prognostic biomarker for localized anal cancer","volume":"31","author":"Morris","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.bulcan.2026.06.003_bib0455","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1158\/1078-0432.CCR-18-2984","article-title":"Clinical validity of HPV circulating tumor DNA in advanced anal carcinoma: an ancillary study to the epitopes-HPV02 trial","volume":"25","author":"Bernard-Tessier","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.bulcan.2026.06.003_bib0460","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000452766","article-title":"EGFR inhibitors in patients with advanced squamous cell anal carcinomas: a single-institution experience","volume":"92","author":"Kim","year":"2017","journal-title":"Oncology"},{"issue":"8","key":"10.1016\/j.bulcan.2026.06.003_bib0465","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1097\/CAD.0000000000000383","article-title":"Epidermal growth factor receptor inhibition in metastatic anal cancer","volume":"27","author":"Rogers","year":"2016","journal-title":"Anti-Cancer Drugs"},{"issue":"3","key":"10.1016\/j.bulcan.2026.06.003_bib0470","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.dld.2022.08.026","article-title":"Efficacy and tolerance of cetuximab in combination with 5 FU plus irinotecan based chemotherapy in metastatic squamous cell anal carcinoma","volume":"55","author":"Valery","year":"2023","journal-title":"Dig Liver Dis"},{"issue":"10","key":"10.1016\/j.bulcan.2026.06.003_bib0475","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1080\/14737140.2020.1810573","article-title":"Outcomes with anti-EGFR monoclonal antibodies in metastatic and recurrent anal squamous cell carcinoma","volume":"20","author":"Rogers","year":"2020","journal-title":"Expert Rev Anticancer Ther"},{"issue":"16","key":"10.1016\/j.bulcan.2026.06.003_bib0480","doi-asserted-by":"crossref","first-page":"6853","DOI":"10.1002\/cam4.2558","article-title":"Mitomycin and 5-fluorouracil for second-line treatment of metastatic squamous cell carcinomas of the anal canal","volume":"8","author":"Saint","year":"2019","journal-title":"Cancer Med"},{"issue":"2","key":"10.1016\/j.bulcan.2026.06.003_bib0485","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000361051","article-title":"Carboplatin and paclitaxel treatment is effective in advanced anal cancer","volume":"87","author":"Kim","year":"2014","journal-title":"Oncology"},{"issue":"12","key":"10.1016\/j.bulcan.2026.06.003_bib0490","first-page":"4637","article-title":"Single-agent paclitaxel in advanced anal cancer after failure of cisplatin and 5-fluorouracil chemotherapy","volume":"31","author":"Abbas","year":"2011","journal-title":"Anticancer Res"},{"issue":"10","key":"10.1016\/j.bulcan.2026.06.003_bib0495","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1002\/cam4.3886","article-title":"Nonplatinum-based therapy with Paclitaxel and Capecitabine for advanced squamous cell carcinomas of the anal canal: a population-based Danish anal cancer group study","volume":"10","author":"Truelsen","year":"2021","journal-title":"Cancer Med"},{"issue":"5","key":"10.1016\/j.bulcan.2026.06.003_bib0500","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/annonc\/mdx029","article-title":"Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal","volume":"28","author":"Ott","year":"2017","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2026.06.003_bib0505","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1200\/JCO-25-00929","article-title":"NCI9673 (Part B): ETCTN randomized phase II study of nivolumab with or without ipilimumab in refractory, metastatic squamous cell carcinoma of the anal canal","volume":"44","author":"Morris","year":"2026","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.bulcan.2026.06.003_bib0255","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1158\/1078-0432.CCR-24-1512","article-title":"Phase II trial of atezolizumab and bevacizumab for treatment of HPV-positive unresectable or metastatic squamous cell carcinoma of the anal canal","volume":"31","author":"Morris","year":"2025","journal-title":"Clin Cancer Res"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745512600367X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745512600367X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:45:48Z","timestamp":1789764348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000745512600367X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":51,"alternative-id":["S000745512600367X"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.06.003","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer du canal anal m\u00e9tastatique ou en rechute inop\u00e9rable\u00a0: approches th\u00e9rapeutiques et perspectives d\u2019\u00e9volution","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}